N4 Pharma ( (GB:N4P) ) has issued an update.
N4 Pharma announced that all resolutions were passed at its General Meeting, allowing the issuance of 294,719,650 shares and associated warrants. The new shares are set to be admitted to trading on AIM, increasing the total number of voting rights to 832,280,349. This development is a strategic step for N4 Pharma, potentially enhancing its market position and providing opportunities for stakeholders to engage with the company under the FCA’s Disclosure and Transparency Rules.
More about N4 Pharma
N4 Pharma is a pre-clinical biotech company focused on developing Nuvec®, a proprietary gene delivery system designed to enhance advanced therapies for cancer and other diseases. The company aims to leverage RNA therapeutics to impact a wide range of diseases, offering advantages such as multi-RNA delivery, ease of manufacturing, and stability. N4 Pharma is progressing towards first-in-human clinical data to secure significant licensing deals for its Nuvec® platform.
YTD Price Performance: -27.88%
Average Trading Volume: 2,085,811
Technical Sentiment Signal: Buy
Current Market Cap: £4.61M
See more insights into N4P stock on TipRanks’ Stock Analysis page.